Drug allergy: the mechanisms of development, symptoms, diagnostics, and treatment. Measures preventing the drug allergy презентация

Содержание

Слайд 2

Adverse Drug Reactions (ADRs) include all unintended pharmacologic effects of a drug except:

● Therapeutic Failures,
● Intentional Overdosage,
● Abuse of the Drug, or
● Errors in Administration.
ADRs are categorized into:
Type A: predictable (75%) – dose dependent, related to the known pharmacologic actions of the drug, and occur in otherwise healthy individuals
Type B: unpredictable (25%) reactions - generally dose independent, unrelated to the actions of
the drug, and occur
only in SUSCEPTIBLE INDIVIDUALS.

Adverse Drug Reactions (ADRs) include all unintended pharmacologic effects of a drug except:

Слайд 3

Unpredictable reactions:
● Drug Intolerance
● Drug Idiosyncrasy
● Drug Allergy

Pseudoallergic Reactions.
Drug allergy is a non-predictable immunologically mediated ADR to a pharmaceutical and/or formulation agent in a sensitized person.
Drug allergy differs from drug toxicity in many ways:
● The lesion produced by allergy is lower in incidence
● It is unpredictable;
● Prior exposure to the drug may cause sensitization;
● The lesion is dose independent and rash, fever,
eosinophilia and blood dyscrasias can occur.

Unpredictable reactions: ● Drug Intolerance ● Drug Idiosyncrasy ● Drug Allergy ● Pseudoallergic

Слайд 4

A. Humoral Type:
Type I (Anaphylactic) reactions - Immediate hypersensitivity reactions are IgE mediated:


Urticaria, Itching, Subepidermal Necrolysis – Lyell's syndrome, Angioedema, Asthma, Rhinitis, Anaphylactic Shock.
Type II (Cytolytic) reactions are mediated by IgG or IgM:
Blood Transfusion Reactions, Haemolytic Disease of Newborns, Autoimmune Haemolytic Anemia, Thrombocytopenia, Agranulocytosis, Aplastic Anaemia, Haemolysis, Organ Damage (the liver, kidney, muscle), Systemic Lupus Erythematosus and Some Drug Reactions.
Type III (Retarded) reactions are mediated by circulating antibodies (predominantly mopping antibody, IgG):
Serum sickness - symptoms develop within 7-10 days and include Urticaria, Lymphadenopathy, Myalgia, Arthralgia, Fever,
Polyarthritis Nodosa, Stevens-Johnson syndrome.
Systemic lupus erythematosus is an autoimmune disorder that may be induced by Hydralazine, Novocainamide, Isoniazid and other drugs.

A. Humoral Type: Type I (Anaphylactic) reactions - Immediate hypersensitivity reactions are IgE

Слайд 5

B. Cell Mediated:
Type IV (Delayed hypersensitivity) reactions:
several hours or days after exposure

to the antigen-
are cell-mediated through production of sensitized
T-lymphocytes carrying receptors for the antigen.
On contact with antigen these T cells produce limphokines which attract granulocytes and generate an inflammatory response, e.g., contact dermatitis, some rashes, fever, photosensitization.

B. Cell Mediated: Type IV (Delayed hypersensitivity) reactions: several hours or days after

Слайд 6

The antigen reacts with reaginic IgE antibodies, bound to the surface of mast

cells and basophils, leading to their degranulation and liberation of histamine and other mediators:
●Those that ⭡Vascular Permeability and contract smooth muscles: Histamine, PAF, SRS-A, Bradykinin.
●Those that are chemotactic for or activate other pro-inflammatory cells: Leukotriene B4,
Eosinophil and Neutrophil Chemotactic Factors.
●Those that modulate the release of other mediators: Bradykinin, PAF, Prostaglandins.
●Those which cause termination of the immune inflammatory response.

The antigen reacts with reaginic IgE antibodies, bound to the surface of mast

Слайд 7

DRUG ALLERGY

The most dangerous type of ADRs.
45% reports of AR/SE of drugs in

town of Zaporizhia.
900 reports of allergic reactions on drugs
(36% reports of AR/SE of drugs) in Ukraine
during 1996-2008.
Latent forms of hypersensitivity to drugs –
in 10-15% world population and
20% healthy people (according to WHO).

DRUG ALLERGY The most dangerous type of ADRs. 45% reports of AR/SE of

Слайд 8

Allergic Anamnesis Ignoring

Analgin, Aspirin, Ampicillin were administered in patients with allergic anamnesis

(sometimes with other trade names).
Severe allergic reactions were observed –
Anaphylactic Shock, Quincke‘s edema, Toxic Dermatitis.
Allergic reacitons on Flemoxin and Grunamox in patients with drug allergy to Amoxicillin
Allergic reacitons on Solpadein the active substance of which is Paracetamole.
The main reason of manifestation – absence of knowledge of numerous trade names of
Generic Drugs containing the Same Active Agents.

Allergic Anamnesis Ignoring Analgin, Aspirin, Ampicillin were administered in patients with allergic anamnesis

Слайд 9

The various subtypes of T lymphocytes
(Cytotoxic, Helper and Suppressor) and their responses

constitute Cell Mediated Immunity (CMI).
They regulate Humoral Immunity, B lymphocyte function.
T-cells carrying CD4+ antigen are responsible for
the HELPER function and the delayed hypersensitivity.
Th1 cells enhance CMI but inhibit Humoral Immunity.
Th2 cells have the opposite effect.
T-cells carrying CD8+ antigen are mainly responsible
for the CYTOTOXIC and SUPPRESSOR functions.

The various subtypes of T lymphocytes (Cytotoxic, Helper and Suppressor) and their responses

Слайд 10

The spectrum of drug allergic reactions and syndromes

DRESS: Drug Rash with Eosinophilia and

Systemic Symptoms;
TEN - Toxic Epidermal Necrolysis

The spectrum of drug allergic reactions and syndromes DRESS: Drug Rash with Eosinophilia

Слайд 11

Atopic allergy and targets for therapy
Allergen Avoid allergen
?
IgE synthesis Desensitize
? Stabilize

Mast Cell Membrane
Mast cells Degranulation (Cromolyn, Ketotifen, Ephedrine)
? Mediator Antagonists
Mediator Release (Antihistaminics, Anti-cytokines)
? Late Phase Inhibitors
Local Anaphylaxis (ATOPY) (Glucocorticoids, Indomethacin)
Nose GIT Lungs Skin
(Hay, fever) (Pain, Diarrhea) (Asthma) (Eczema)

Atopic allergy and targets for therapy Allergen Avoid allergen ? IgE synthesis Desensitize

Слайд 12

Aspirin and other NSAIDs are reported to account for 21-25% of all Adverse

Drug Reactions

Intake of:
- Analgin
- Diclophenac
- Ketanov
- Baralgetas
produced severe Bronchoobstructive Syndrome in
patients with Aspirin Asthma.
Aspirin-induced asthma refers to the development of acute bronchoconstriction, profuse rhinorrhea and
skin flushing in asthmatic individuals following
the ingestion of aspirin.

Aspirin and other NSAIDs are reported to account for 21-25% of all Adverse

Слайд 13

Cyclo-oxygenase (COX) and Lipoxygenase (LO) are
2 main pathways of the metabolism of

Arachidonic Acid
The COX pathway converts Arachidonic Acid to Prostaglandins, Prostacyclin and Thromboxane A.
Attacks of asthma precipitated by Aspirin like drugs are due to the inhibition of COX in airways of the sensitive patients:
the Bronchoconstrictor PgF at the expense of
the Bronchodilator PgE2 due to altered COX response.
The LO Pathway converts Arachidonic Acid to
Leukotriene A4 (LT A4) further hydroxylated to LT B4.
LT B4 is a potent chemotactic agent.
The Sulphidopeptide Leukotrienes LT C4, LT D4 and LT E4 are constrictors of the smooth muscle of the airway
Aspirin-induced asthma may relate to the inhibition of COX, resulting in the "shunting" of Arachidonic Acid cascade to the 5- Lipoxygenase pathway.

Cyclo-oxygenase (COX) and Lipoxygenase (LO) are 2 main pathways of the metabolism of

Слайд 14

ANTIALLERGIC DRUGS
1. Drugs Stabilizing Mast Cell Membrane:
Glucocorticoids: Prednisolone, Hydrocortisone
Antihistamine H1 : Ketotifen
a

Mast cell stabilizer: Cromolyn
β-adrenomimetics: Adrenaline, Ephedrine
Methylxanthines: Euphylline (Aminophylline)
2. Antihistamine H1 agents: Dimedrol, Diprazine, Loratadine
3. Agents eliminating generalized symptoms of immediate allergic reactions:
Adrenomimetics: Adrenaline
Methylxanthines: Euphylline, Theophylline
Ca2+ preparations: Calcium chloride, Ca2+ gluconate
4. Agents decreasing tissue damage: Glucocorticoids

ANTIALLERGIC DRUGS 1. Drugs Stabilizing Mast Cell Membrane: Glucocorticoids: Prednisolone, Hydrocortisone Antihistamine H1

Слайд 15

GLUCOCORTICOIDS (GCs)

1. Short-acting: Hydrocortisone acetate Cortisone
2. Intermediate-acting:
Prednisolone
Triamcinolone
3. Long-acting: Betametasone,
Dexametasone
OINTMENTS

for local use - Fluorine-containing:
Synaflan, Flumethasone
AEROSOLS or POWDERS FOR INHALATIONS: Beclometasone
Fluticasone

GLUCOCORTICOIDS (GCs) 1. Short-acting: Hydrocortisone acetate Cortisone 2. Intermediate-acting: Prednisolone Triamcinolone 3. Long-acting:

Слайд 16

Mechanism of Action of Glucocorticoids
Steroid hormones are lipid soluble and cross cell membranes

easily.
Once inside the cell, the hormone molecules bind with specific receptor proteins.
The hormone–receptor complex enters the nucleus of the cell where it activates Gene Expression –
nucleic acids (DNA and RNA) and
the Genetic Code to synthesize
new proteins.

Mechanism of Action of Glucocorticoids Steroid hormones are lipid soluble and cross cell

Слайд 17

Action of GCs on mediators of inflammatory
and immune response:
GCs change Gene Expression:


? Production of prostanoids owing to
Decreased Expression of COX-2
? Generation of cytokines –
IL 1-6, IL-8, TNF-α and cell adhesion factor – through inhibition of transcription of
the relevant genes
? Complement components in the plasma
? Generation of induced NO
? Histamine release from basophils
? IgG production.

Action of GCs on mediators of inflammatory and immune response: GCs change Gene

Слайд 18

Adverse effects of GCs: Cushing’s syndrome:

Moon face, with red cheeks
Thin arms and

legs: muscle wasting
?BP, Itracranial Hypertension
Osteoporosis
Cataracts
Thinning of skin
Increased abdominal fat
Buffalo hump
Euphoria
Depression or emotional lability
Avascular necrosis of femoral head
?Appetite, Obesity,
Hyperglycemia, Diabetes

Adverse effects of GCs: Cushing’s syndrome: Moon face, with red cheeks Thin arms

Слайд 19

Cromolyn sodium (caps. 20 mg for inhalation) and
Nedocromil (aerosol: 2 mg/dose) stabilize

mast cells and prevent the release of bronchoconstrictive and inflammatory substances when mast cells are confronted with allergens and other stimuli.
They stabilize the mast cell membrane and inhibit release of the mediators of Type I allergic reaction, including: histamine and Slow Reacting Substance of Anaphylaxis (SRS-A) from sensitized must cells.
Pretreatment with cromolyn blocks allergen-induced and exercise-induced bronchoconstriction by acting on inflammatory cells such as eosinophils.

Cromolyn sodium (caps. 20 mg for inhalation) and Nedocromil (aerosol: 2 mg/dose) stabilize

Слайд 20

Ketotifen (tab. 1 mg), a cromolyn analog, is an antihistaminic (H1) and mast

cell stabilizer.
● It inhibits stimulation of immunogenic and inflammatory cells (mast cells, macrophages, eosinophils, lymphocytes, neutrophils) and mediator release.
● It is believed to inhibit airway inflammation induced by
platelet activating factor (PAF).
Ketotifen prevents bronchial asthma attacks.
● It also produces relief in patients with rhinitis, atopic dermatitis, conjunctivitis, urticaria, food allergy, migraine
Adverse effects: sedation, dry mouth, dizziness, nausea,
weight gain.

Ketotifen (tab. 1 mg), a cromolyn analog, is an antihistaminic (H1) and mast

Слайд 21

H1-Receptors:
Exocrine excretion => ?Nasal and Bronchial mucus
Bronchial smooth muscle constriction

=> bronchospasm
Intestinal smooth muscle contraction =>
cramps and diarrhea
Sensory nerve endings: itch and pain
H2-Receptors:
Stomach: Stimulation of Gastric Hydrochloric Acid Secretion
H1- and H2-Receptors:
Cardiovascular system: ?BP and ?HR
Skin:
‘Triple Response’ – Wheal formation, Reddening, Flare

H1-Receptors: Exocrine excretion => ?Nasal and Bronchial mucus Bronchial smooth muscle constriction =>

Слайд 22

Слайд 23

H1-Receptor Antagonists
I GENERATION (SEDATIVE):
Dimedrol (Diphenhydramine)
Diprazine (Promethazine)
Suprastine (Chloropyramine)
Diazoline
Tavegyl (Clemastin)
II GENERATION (NON-SEDATIVE):

Loratadine (Claritin)
Terfenadine
Astemizole
Phencarol (Quifenadine)
III GENERATION (ACTIVE METABOLITES):
Telfast (Fexofenadine)
Zirtek (Cetirizine)

H1-Receptor Antagonists I GENERATION (SEDATIVE): Dimedrol (Diphenhydramine) Diprazine (Promethazine) Suprastine (Chloropyramine) Diazoline Tavegyl

Слайд 24

Pharmacodynamics of antihistamine H1 blockers
⮞ Block the actions of histamine by reversible

competitive
antagonism at the H1-receptor
⮞ Antagonist effects at other receptors:
⮞ M - Cholinoceptors
⮞ α1 - Adrenoreceptors
⮞ 5-Hydrohytryptamine (5-HT) receptors
Diprazin ⮞ Dimedrol ⮞ Suprastin ⮞ Diazolin

Pharmacodynamics of antihistamine H1 blockers ⮞ Block the actions of histamine by reversible

Слайд 25

Dimedrol (Diphenhydramine)-Tab 0.05 g, amp 1%-1 ml
competes to H1 receptors on the

smooth muscle of
the bronchi, GIT, uterus, and large blood vessels.
By binding to receptors, suppresses histamine-induced allergic symptoms, even though it does not prevent its release.
Central antimuscarinic actions is responsible for antivertigo, antiemetic, and antidyskinetic action.
Clinical uses:
⮞ Allergy symptoms
⮞ Motion sickness
⮞ Parkinson’s disease
⮞ Nonproductive cough
⮞ Insomnia

Dimedrol (Diphenhydramine)-Tab 0.05 g, amp 1%-1 ml competes to H1 receptors on the

Слайд 26

Terfenadine (Claritin)-.
● blocks cardiac K+ channels, prolongs Q-T and
has occasionally produced

Polymorphic Ventricular Tachycardia.
The risk is increased in liver disease or when inhibitors of CYP3A4 are administered concurrently – because larger amounts of unchanged drug reach systemic circulation.
Erythromycin, Clarithromycin, Ketoconazole and Itraconazole
are the drugs precipitating their
cardiotoxicity as they block
microsomal CYP-450 enzymes.
Because of this risk,
Terfenadine has been withdrawn
by most manufactures.
Clinical use: allergic rhinitis

Terfenadine (Claritin)-. ● blocks cardiac K+ channels, prolongs Q-T and has occasionally produced

Слайд 27

Sympathomimetics:
Adrenaline h/ch - 0.1% sol. 0.3-0,5-1 ml in 2-3 ml of 0.9% NCl

solution SC in the region of injection and around it,
SL or intratracheal instillation,
Mesaton 1% sol. 1-2 ml IV in
0.9% NaCl solution
Noradrenaline h/t 0.2% in
0.9% NCl solution IV infusion
Glucocorticoids:
Prednisolone 3% solution 30-90 mg and more IV
in 0.9% NCl solution

Broncholytics:
Euphylline 2.4% sol.
3-5-10 ml IV
in 0.9% NaCl solution

Oxygen inhalation for hypoxia control or
prevention

Enzyme preparations:
Penicillinase 1000 000 UA in 2 ml of 0.9% NaCl solution in the region of injection

Cardiac Glycosides:
Strophanthine
0.025% 1-2 ml IV in
0.9% NCl solution

Anaphylactic shock

Sympathomimetics: Adrenaline h/ch - 0.1% sol. 0.3-0,5-1 ml in 2-3 ml of 0.9%

Слайд 28

Drugs used to treat Delayed Type Hypersensitivity Reactions:
I. IMMUNOSUPRESSANTS - suppressing

mainly
cell-mediated immunity:
1.Inhibitors of IL-2 production or action:
Cyclosporine (Sandimmune)
Tacrolimus
2.Inhibitors of cytokine gene expression:
Glucocorticoids: Prednisolone
3. Antitumor Cytotoxic Agents:
a) Alkylating agents: Cyclophosphan
b) Antimetabolites: Azathioprine, Mercaptopurine, Methotrexate
4.Blockers of the T-cell surface molecules involved in signaling - Monoclonal Antibodies: Basiliximab and Daclizumab

Drugs used to treat Delayed Type Hypersensitivity Reactions: I. IMMUNOSUPRESSANTS - suppressing mainly

Слайд 29


Drugs used to treat
Delayed Type Hypersensitivity Reactions:
II. Drugs decreasing tissue damage


1. Glucocorticoids
2. NSAIDs

Drugs used to treat Delayed Type Hypersensitivity Reactions: II. Drugs decreasing tissue damage

Имя файла: Drug-allergy:-the-mechanisms-of-development,-symptoms,-diagnostics,-and-treatment.-Measures-preventing-the-drug-allergy.pptx
Количество просмотров: 21
Количество скачиваний: 0